ADMA Biologics Inc vs Amylx Pharmaceuticals Inc — how do they compare? ADMA Biologics Inc trades at $9.81 (market cap $2.22B), while Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.64B). The key difference: Amylx Pharmaceuticals Inc is the larger of the two by market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | AMLX | |
|---|---|---|
Market Cap | $2.22B | $2.64B |
Sector | Health | Health |
52-Week High | $20.38 | $24.19 |
52-Week Low | $7.60 | $7.82 |
Enterprise Value | $2.29B | $2.39B |
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →